Recent years have seen an increasing interest in the use of low dose naltrexone (LDN) for off-label treatment of pain in diseases as fibromyalgia, multiple sclerosis and morbus Crohn. The evidence is poor, with only few randomized double-blind placebo-controlled studies. The studies currently available are reviewed in this paper. LDN could be a potentially useful drug in the future for the treatment of pain in fibromyalgia, but more studies are needed to verify that it is superior to placebo, and currently it cannot be recommended as first-line therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
dose naltrexone
8
treatment pain
8
[low dose
4
naltrexone treatment
4
treatment pain]
4
pain] years
4
years increasing
4
increasing interest
4
interest low
4
low dose
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!